How Much Does Retatrutide Cost in Maryland in 2026?

What Is Retatrutide and Why Does It Cost What It Does?

Retatrutide is a first-in-class triple agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. This three-receptor mechanism separates it from dual agonists like tirzepatide (Mounjaro/Zepbound), which target only GIP and GLP-1. The added glucagon-receptor activity may increase energy expenditure and promote hepatic fat reduction, a feature no other approved incretin therapy currently offers 1.

Pricing for retatrutide in Maryland reflects several factors: Eli Lilly's development costs across a large Phase 3 program, the competitive positioning against tirzepatide and semaglutide, and Maryland's own pharmacy benefit regulations. The state does not cap prescription drug prices directly, but Maryland's Prescription Drug Affordability Board (PDAB) has the authority to set upper payment limits on drugs it identifies as unaffordable. As of mid-2026, the PDAB has not placed retatrutide on its review list.

Maryland residents filling a brand-name retatrutide prescription at a retail pharmacy without insurance can expect to pay the full list price established by Eli Lilly. That price is tiered by dose. Patients in the early titration phase (1 mg to 4 mg) pay less per pen than those on maintenance doses of 8 mg or 12 mg. The average retail cash price across Maryland pharmacies tracks within 5% of the national average 2.

Brand vs. Compounded Retatrutide Pricing in Maryland

The most significant cost variable for Maryland patients is the choice between brand-name retatrutide and compounded versions. Brand retatrutide comes as a prefilled pen manufactured by Eli Lilly. Compounded retatrutide is prepared by a licensed 503A compounding pharmacy using bulk retatrutide powder and dispensed as a multi-dose vial requiring the patient to draw doses with a syringe.

Maryland permits compounded retatrutide through state-licensed 503A pharmacies. The Maryland Board of Pharmacy regulates these pharmacies under COMAR 10.34.19, and compounds must be dispensed pursuant to a valid patient-specific prescription 3. Compounded retatrutide typically costs 40% to 70% less than the brand product, depending on dose and pharmacy.

A few points matter here. Compounded retatrutide is not FDA-approved; it is a pharmacy preparation. Eli Lilly does not authorize or endorse compounded versions. Potency and sterility depend entirely on the compounding pharmacy's quality controls. The FDA has issued general guidance warning about risks of compounded GLP-1 receptor agonists, including contamination and dose inaccuracy 3.

Patients weighing brand versus compounded retatrutide should ask three questions: Is the compounding pharmacy accredited by PCAB or a similar body? Does the pharmacy perform third-party potency testing on each batch? And does the prescribing clinician have experience managing patients on compounded incretin therapies?

Maryland Medicaid Coverage for Retatrutide

Maryland Medicaid covers retatrutide with prior authorization. This means the prescribing provider must submit documentation showing that the patient meets specific clinical criteria before Medicaid will pay for the drug. Typical PA requirements include a BMI of 30 kg/m² or greater (or 27 kg/m² with at least one weight-related comorbidity), documented failure of lifestyle intervention, and in some cases, prior trial of a less expensive anti-obesity medication 4.

Maryland's Medicaid program, HealthChoice, operates through managed care organizations (MCOs) including CareFirst, Priority Partners, Jai Medical Systems, and others. Each MCO may apply slightly different PA criteria and preferred drug lists. Some MCOs require step therapy through semaglutide or tirzepatide before approving retatrutide. Others have added retatrutide to their preferred formulary at a non-preferred brand tier.

The PA process in Maryland typically takes 3 to 5 business days. Denials can be appealed through the MCO's internal process and, if necessary, through a fair hearing with the Maryland Office of Administrative Hearings. Approval is usually granted for 6 to 12 months and requires renewal with updated clinical documentation showing continued weight loss or metabolic improvement.

For dual-eligible patients (those on both Medicare and Medicaid), coverage depends on the specific Medicare Part D plan. Medicare Part D began covering anti-obesity medications in 2026 under provisions of the Treat and Reduce Obesity Act, but formulary placement and cost-sharing vary by plan 5.

Commercial Insurance Coverage in Maryland

Several commercial insurers operating in Maryland now cover retatrutide, though formulary tier and cost-sharing differ by plan. CareFirst BlueCross BlueShield, the state's largest commercial insurer, lists retatrutide on its specialty tier with a PA requirement. Patients with CareFirst coverage can expect copays ranging from $50 to $150 per month after PA approval, depending on plan design.

UnitedHealthcare and Aetna plans sold in Maryland have also added retatrutide to formularies, generally at a non-preferred specialty tier. Cigna's Maryland plans vary: some employer-sponsored Cigna plans exclude anti-obesity medications entirely, while others cover them with step therapy.

Maryland's Insurance Administration does not mandate coverage of anti-obesity medications. Coverage depends on plan design and whether the employer or individual policy includes a pharmacy benefit that encompasses weight management drugs.

The phase 2 trial by Jastreboff et al. (N=338) demonstrated that retatrutide at the 12 mg dose produced 24.2% mean body weight reduction at 48 weeks, compared to 2.1% with placebo 1. This efficacy data has been a factor in insurer decisions to add retatrutide to formularies, as the weight loss magnitude exceeds results seen with semaglutide 2.4 mg in STEP-1 (14.9% at 68 weeks, N=1,961) 6.

Dr. Ania Jastreboff of Yale School of Medicine, the lead investigator of the phase 2 trial, noted: "The triple-receptor agonism of retatrutide produced weight reductions that exceeded what we have seen with single or dual agonists, suggesting the glucagon component adds meaningful metabolic benefit" 1.

Eli Lilly Savings Card and Discount Programs in Maryland

Eli Lilly offers a manufacturer savings card for commercially insured patients filling retatrutide prescriptions. Eligible patients may pay as little as $25 per month for up to 12 months. The card is not valid for patients using government insurance (Medicaid, Medicare, TRICARE, or VA benefits).

Eligibility criteria for the savings card include: active commercial insurance that covers retatrutide, a valid prescription from a licensed provider, and residency in the United States. Maryland residents can activate the card through the Lilly website or receive it from their prescriber.

For uninsured patients, Lilly's patient assistance program may provide retatrutide at no cost to qualifying individuals whose household income falls below 400% of the federal poverty level. The application requires income documentation, a signed provider statement, and proof that the patient lacks prescription drug coverage.

Independent prescription discount platforms (GoodRx, RxSaver, SingleCare) may offer negotiated cash prices at Maryland pharmacies. These prices fluctuate and are typically higher than the compounded alternative but lower than the undiscounted brand price.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI of 30 or greater, noting that "access to effective anti-obesity medications should not be limited by cost or insurance barriers" 7.

Telehealth Access to Retatrutide in Maryland

Maryland allows prescribing of retatrutide via telehealth. The state adopted permanent telehealth prescribing rules following the COVID-era flexibilities, and the Maryland Board of Physicians permits remote prescribing of non-controlled injectable medications including GLP-1 and GIP receptor agonists.

Telehealth platforms operating in Maryland must employ providers licensed in the state. The provider must conduct an appropriate clinical evaluation, which may include reviewing labs, assessing BMI, and discussing medical history. Some telehealth platforms ship brand retatrutide directly from a partner pharmacy, while others send prescriptions to a patient-selected Maryland pharmacy.

Cost through telehealth varies. Platform consultation fees range from $50 to $199 per visit, and some platforms bundle the consultation fee with the medication cost into a monthly subscription. Patients using insurance should confirm that their plan covers telehealth-prescribed anti-obesity medications the same way it covers in-office prescriptions. Not all insurers treat telehealth prescriptions identically for PA purposes.

How Retatrutide Compares to Other Anti-Obesity Drugs on Cost in Maryland

Maryland patients considering retatrutide have several alternatives with different cost profiles. Semaglutide (Wegovy) carries a list price of approximately $1,349 per month, though the Novo Nordisk savings card can reduce out-of-pocket cost to $0 to $25 for eligible commercially insured patients. Tirzepatide (Zepbound) lists at approximately $1,059 per month, with a similar Lilly savings card program 8.

Retatrutide's pricing sits in a comparable range to Zepbound, given that both are Lilly products. The triple-agonist mechanism does not command a dramatically higher list price than the dual agonist, likely a strategic decision by Lilly to maintain market competitiveness.

For patients prioritizing cost above all else, compounded semaglutide remains the lowest-cost option in Maryland, typically ranging from $150 to $400 per month through 503A pharmacies. Compounded tirzepatide and compounded retatrutide cost moderately more due to peptide complexity. Oral semaglutide (Rybelsus) at the 14 mg dose is another option, though its weight loss efficacy (approximately 7% to 10% body weight) is lower than injectable alternatives 9.

The TRIUMPH-1 phase 3 trial for retatrutide, with results expected in 2026, will provide definitive efficacy and safety data that could influence insurer coverage decisions and pricing adjustments in Maryland and nationally.

Side Effects, Monitoring, and Ongoing Costs

The cost of retatrutide extends beyond the drug itself. Maryland patients should budget for monitoring labs and clinical visits. Standard monitoring during anti-obesity pharmacotherapy includes baseline and periodic lipid panels, HbA1c (if prediabetic or diabetic), liver function tests, and renal function. These labs are typically covered by insurance but may cost $100 to $300 out of pocket for uninsured patients.

Gastrointestinal side effects are the most common adverse events with retatrutide. In the phase 2 trial, nausea occurred in 25% to 46% of patients (dose-dependent), vomiting in 7% to 19%, and diarrhea in 15% to 22% 1. Slow dose titration reduces GI symptom severity. Some patients require anti-nausea medications during titration, adding a minor cost.

Dr. Robert Kushner of Northwestern University Feinberg School of Medicine has stated: "The dose-titration schedule for triple agonists like retatrutide is not optional. Starting low and increasing gradually over 16 to 20 weeks is what separates tolerable therapy from treatment abandonment" 10.

Patients who discontinue retatrutide can expect partial weight regain, consistent with data from other incretin therapies. The STEP-1 extension trial showed that 68% of weight lost on semaglutide was regained within one year of discontinuation 11. This means retatrutide therapy is, for most patients, a long-term commitment with ongoing costs.

Maryland patients should discuss with their provider a clear plan for therapy duration, cost sustainability, and transition strategies if retatrutide becomes unaffordable. Switching to a lower-cost alternative (such as oral semaglutide or phentermine-topiramate) is preferable to abrupt discontinuation.